Team Hewins LLC Takes $549,000 Position in Sanofi (NASDAQ:SNY)

Team Hewins LLC bought a new stake in Sanofi (NASDAQ:SNY) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 11,047 shares of the company’s stock, valued at approximately $549,000.

Other hedge funds also recently modified their holdings of the company. Boston Partners raised its holdings in shares of Sanofi by 1.9% during the fourth quarter. Boston Partners now owns 13,032,746 shares of the company’s stock worth $648,617,000 after acquiring an additional 245,682 shares in the last quarter. Morgan Stanley raised its holdings in Sanofi by 4.6% during the third quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock valued at $392,796,000 after buying an additional 323,968 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in Sanofi by 29.8% during the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock valued at $152,279,000 after buying an additional 651,756 shares in the last quarter. Natixis Advisors L.P. raised its holdings in Sanofi by 15.9% during the third quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after buying an additional 346,563 shares in the last quarter. Finally, Brandes Investment Partners LP raised its holdings in Sanofi by 64.6% during the fourth quarter. Brandes Investment Partners LP now owns 1,770,572 shares of the company’s stock valued at $88,051,000 after buying an additional 694,957 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Trading Down 0.9 %

SNY stock traded down $0.44 during trading on Friday, hitting $48.56. The company had a trading volume of 1,362,630 shares, compared to its average volume of 1,986,742. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average price of $48.27 and a 200-day moving average price of $48.20. Sanofi has a 12 month low of $42.63 and a 12 month high of $55.72. The stock has a market cap of $122.84 billion, a price-to-earnings ratio of 24.45, a PEG ratio of 1.57 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, April 25th. The company reported $0.96 EPS for the quarter, hitting analysts’ consensus estimates of $0.96. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The firm had revenue of $11.36 billion during the quarter, compared to analyst estimates of $11.75 billion. As a group, analysts predict that Sanofi will post 4.12 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a $1.478 dividend. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. This represents a dividend yield of 2.98%. Sanofi’s payout ratio is 74.37%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.